Fragment 176-191
Also known as: HGH Frag 176-191, AOD-9604 analog
Modified growth hormone fragment focused purely on lipolysis without GH receptor activation.
Evidence
Emerging
FDA status
Not FDA-approved
Source
Synthetic hGH fragment (amino acids 176-191)
Overview
Modified growth hormone fragment focused purely on lipolysis without GH receptor activation.
Mechanism of Action
C-terminal fragment of hGH targeting beta-3 adrenergic receptors on adipocytes, stimulates lipolysis and inhibits lipogenesis, no GH receptor binding (no IGF-1 elevation or glucose effects), studied for fat breakdown.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Fat breakdown in animal studies
- No effect on blood sugar or insulin
- Fat tissue in animal studies
- No IGF-1 increase
- Lean mass (animal studies)
- Side effects (little human data)
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Fragment 176-191 isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Preclinical studies, limited human data
Preclinical evidence for lipolysis. Human trials show good safety but mixed efficacy results for weight loss. Mechanisms well-understood but clinical validation limited.
Safety Information
Potential Side Effects
- •Injection site reactions
- •Rare headache
Contraindications
- Pregnancy
- Breastfeeding
Interactions
- ⚠None well-documented
Quick Facts
Related Peptides
AOD-9604
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Semaglutide
Weekly GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and other uses.
Tirzepatide
Weekly GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea.